Fresh analysis reveals that individuals who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain lost weight far faster than those who end traditional diet and exercise programs.
Research printed in a leading health publication demonstrates that while obese individuals can lose about a fifth of their total mass while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Users using these treatments should be cognizant of the danger of quick rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb.
This pace of regain implies a return to original weight within about a year and a half.
Comparing Approaches
The research, which looked at dozens of trials involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with other pills.
Researchers emphasize that individuals who lose weight through lifestyle changes alone generally see a more gradual weight regain—approximately 100 grams monthly—after stopping.
The Reason for the Rapid Rebound
Nutrition scientists propose the way of the drugs explains the accelerated rebound.
These medications mimic a natural hormone called GLP-1, which helps regulate appetite.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' leads to hunger is no longer kept in check, making binge eating much more probable."
A Lifelong Condition?
Health authorities advise the injections for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts contend that, considering the high risk of relapse, the therapy might need to be long-term.
This view is echoed by pharmaceutical companies, who state that the findings "emphasize the chronic character of obesity," comparing it to managing diseases like diabetes.
User Accounts
Individuals who have discontinued the medication describe a intense return of hunger.
"I experienced a trigger that goes on and you become ravenous," described one woman.
The struggle is compounded if users have not established permanent lifestyle or habit modifications during treatment.
Growing Interest
Figures suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Adoption is higher among women compared to males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, experts caution that while the jabs are powerful agents for weight loss, they are not a permanent fix and maintained weight loss likely depends on ongoing behavioural management.
